{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:07Z","timestamp":1791979087236,"version":"4.4.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ministry of Science and Technology","award":["110-2628-B-002-059"],"award-info":[{"award-number":["110-2628-B-002-059"]}]},{"name":"Ministry of Science and Technology","award":["110-2326-B-002-003-MY3"],"award-info":[{"award-number":["110-2326-B-002-003-MY3"]}]},{"name":"Ministry of Health and Welfare","award":["MOHW110-TDU-B-211-124002"],"award-info":[{"award-number":["MOHW110-TDU-B-211-124002"]}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"crossref","award":["NTUH 110-S4901"],"award-info":[{"award-number":["NTUH 110-S4901"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Synergistic combinations of daptomycin and \u03b2-lactam antibiotics are currently recommended for treatment of VRE bloodstream infection (BSI). The efficacy of these combinations is jeopardized by VRE inherently resistant to \u03b2-lactam antibiotics. The combination of daptomycin and fosfomycin is recommended as an alternative therapy for VRE BSI; however, clinical data to support use of this combination are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>We conducted a prospective observational multicentre study of patients treated with a combination of daptomycin and fosfomycin for VRE BSI during 2016\u201320. The primary outcome was 28\u2005day mortality. Multivariable logistic regression was performed for outcome analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 106 patients from 1112 VRE BSI episodes. The overall 28\u2005day mortality was 40.6%. The median (IQR) daptomycin dose was 10.18\u2005mg\/kg (9.43\u201310.70). The fosfomycin dose was 16\u2005g\/day (8\u201322.5). Ninety-six isolates were available for MIC testing. The fosfomycin MIC was 32\u2005mg\/L in 6 (6.3%), 64\u2005mg\/L in 68 (70.8%) and \u2265128\u2005mg\/L in 22 (22.9%) isolates. Independent of Charlson comorbidity index and Pitt bacteraemia score, fosfomycin MIC \u2265128\u2005mg\/L [adjusted OR (aOR) = 3.05; 95% CI = 1.01\u20139.19; P = 0.047] and daptomycin dose (aOR = 0.64; 95% CI = 0.43\u20130.97; P = 0.04) predicted mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Higher daptomycin dose and susceptibility to fosfomycin were independently associated with lower mortality in patients with VRE BSI. Our results suggest that higher doses of daptomycin are indicated for VRE BSI, whether or not it is used in combination with fosfomycin. The combination was less effective for patients with fosfomycin-resistant isolates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac023","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T20:11:13Z","timestamp":1643227873000},"page":"1436-1443","source":"Crossref","is-referenced-by-count":17,"title":["Influence of daptomycin dose and fosfomycin susceptibility on outcome of vancomycin-resistant <i>Enterococcus faecium<\/i> bloodstream infections treated with daptomycin and fosfomycin combination"],"prefix":"10.1093","volume":"77","author":[{"given":"Yu-Chung","family":"Chuang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[{"name":"National Taiwan University School of Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hsi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"2022042812400864100_dkac023-B1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","article-title":"Vancomycin-resistant enterococcal infections","volume":"342","author":"Murray","year":"2000","journal-title":"N Engl J Med"},{"key":"2022042812400864100_dkac023-B2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1086\/339211","article-title":"Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center","volume":"34","author":"Lodise","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2022042812400864100_dkac023-B3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/14787210.2015.1001839","article-title":"Therapeutic options for vancomycin-resistant enterococcal bacteremia","volume":"13","author":"Barber","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022042812400864100_dkac023-B4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jac\/dkl393","article-title":"Bactericidal agents in the treatment of MRSA infections\u2014the potential role of daptomycin","volume":"58","author":"French","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022042812400864100_dkac023-B5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/659152","article-title":"Emergence of daptomycin-resistant VRE: experience of a single institution","volume":"32","author":"Kamboj","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022042812400864100_dkac023-B6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022042812400864100_dkac023-B7","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1128\/AAC.00053-15","article-title":"\u03b2-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic\/pharmacodynamic models","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41598-018-19986-8","article-title":"A retrospective clinical comparison of daptomycin vs daptomycin and a \u03b2-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections","volume":"8","author":"Chuang","year":"2018","journal-title":"Sci Rep"},{"key":"2022042812400864100_dkac023-B9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"2022042812400864100_dkac023-B10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: a pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2022042812400864100_dkac023-B11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0732-8893(02)00370-X","article-title":"In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin","volume":"42","author":"Perri","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022042812400864100_dkac023-B12","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2022042812400864100_dkac023-B13","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00502-12","article-title":"Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics","volume":"56","author":"Berti","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B14","doi-asserted-by":"crossref","first-page":"e02633-17","DOI":"10.1128\/AAC.02633-17","article-title":"The combination of daptomycin and fosfomycin has synergistic, potent, and rapid bactericidal activity against methicillin-resistant Staphylococcus aureus in a rabbit model of experimental endocarditis","volume":"62","author":"Garcia-de-la-Maria","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. a randomized clinical trial","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022042812400864100_dkac023-B16","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirtieth Edition: M100","author":"CLSI","year":"2020"},{"key":"2022042812400864100_dkac023-B17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1017\/ice.2019.205","article-title":"A systematic review of central-line-associated bloodstream infection (CLABSI) diagnostic reliability and error","volume":"40","author":"Larsen","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022042812400864100_dkac023-B18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciq154","article-title":"Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia","volume":"52","author":"Chuang","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022042812400864100_dkac023-B19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022042812400864100_dkac023-B20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"2022042812400864100_dkac023-B21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Early administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis","volume":"37","author":"Casapao","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2022042812400864100_dkac023-B22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","article-title":"Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA Adverse Event Reporting System database","volume":"4","author":"Iarikov","year":"2015","journal-title":"Infect Dis Ther"},{"key":"2022042812400864100_dkac023-B23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2022042812400864100_dkac023-B24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2022042812400864100_dkac023-B25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2016.02.006","article-title":"Vancomycin-resistant enterococci: therapeutic challenges in the 21st century","volume":"30","author":"Miller","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2022042812400864100_dkac023-B26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for Gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2022042812400864100_dkac023-B27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B29","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B30","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022042812400864100_dkac023-B31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijantimicag.2019.07.002","article-title":"Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia","volume":"54","author":"Avery","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2022042812400864100_dkac023-B32","first-page":"605","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022042812400864100_dkac023-B33","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1128\/AAC.00687-16","article-title":"Fosfomycin enhances the activity of daptomycin against vancomycin-resistant enterococci in an in vitro pharmacokinetic-pharmacodynamic model","volume":"60","author":"Hall Snyder","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B34","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/jac\/dku113","article-title":"Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic\/pharmacodynamic simulated endocardial vegetation model","volume":"69","author":"Hall Snyder","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"2022042812400864100_dkac023-B35","first-page":"8","article-title":"New microbiological aspects of fosfomycin","volume":"32","author":"Diez-Aguilar","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2022042812400864100_dkac023-B36","doi-asserted-by":"crossref","first-page":"e00342-20","DOI":"10.1128\/AAC.00342-20","article-title":"Oral fosfomycin treatment for enterococcal urinary tract infections in a dynamic in vitro model","volume":"64","author":"Abbott","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B37","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.02099-12","article-title":"Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents","volume":"57","author":"Descourouez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2022042812400864100_dkac023-B39","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812400864100_dkac023-B40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2013.56","article-title":"Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10","volume":"66","author":"Pogue","year":"2013","journal-title":"J Antibiot (Tokyo)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1436\/43480569\/dkac023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1436\/43480569\/dkac023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T12:43:02Z","timestamp":1651149782000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/5\/1436\/6525717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2022,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac023","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,2,10]]}}}